Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

@article{Nilsson2012UpdatedAO,
  title={Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).},
  author={Sten B. Nilsson and Daniel Heinrich and J. M. O'Sullivan and Sophie D Fossa and Ale{\vs} Chodacki and Pawel Jan Wiechno and John P. Logue and Mihalj Seke and Anders Widmark and Dag Clement Johannessen and Peter J. Hoskin and David Martin Bottomley and Robert Coleman and Nicholas John Vogelzang and Charles Gillies O'Bryan-Tear and Jose E Garcia-Vargas and Minghua Shan and Alton Oliver Sartor},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 18_suppl},
  pages={LBA4512}
}
LBA4512 Background: Radium-223 chloride (Ra-223), a targeted alpha-emitter, targets bone metastases (mets) with high-energy alpha-particles of short range (<100 µm). ALSYMPCA, a phase III double-blind, randomized, multinational study, compared Ra-223 plus best standard of care (BSC) vs placebo plus BSC in CRPC patients (pts) with bone mets. In a planned interim analysis (n = 809), based on 314 events, Ra-223 significantly improved overall survival (OS) vs placebo (median 14.0 mo vs 11.2 mo… CONTINUE READING
50 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

Similar Papers

Loading similar papers…